IDEAYA Biosciences (IDYA)
(Delayed Data from NSDQ)
$42.25 USD
-0.14 (-0.33%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $42.23 -0.02 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
IDEAYA Biosciences, Inc. [IDYA]
Reports for Purchase
Showing records 61 - 80 ( 172 total )
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Tomorrow, Ideaya To Review Data for Daro + Crizotinib in MUM Patients
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare- Companies With YE2021 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; Early Activity for IDE397; Darovasertib/Crizotinib Data in Q4:21
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
3Q21 Update - Daro + Crizotinib Data Expected by YE & More 2022 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Busy 2H:21 Ahead Across Precision Oncology Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Update - The Stock Has Rallied, But Still More to Come During 2H2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q21 Results; Strong Balance Sheet; IDE397 Phase 1 Data Expected 4Q21; Lowering PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
2H2021 Catalyst Calendar: Positive Outlook On Our Coverage & The Sector
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Ideaya Highlights Clinical Progress and Reaffirms Readouts for 2H2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IDE397 Pharmacodynamics Update; Promising Darovasertib Combination Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: IDEAYA Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
IDE397 Already on Target; Darovasertib Combos Update
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R